{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:25Z","timestamp":1788848425269,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002243"],"award-info":[{"award-number":["UL1TR002243"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201300023I"],"award-info":[{"award-number":["HHSN272201300023I"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.vaccine.2024.126702","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T03:43:41Z","timestamp":1736480621000},"page":"126702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59\u00ae"],"prefix":"10.1016","volume":"47","author":[{"given":"Sharon E.","family":"Frey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Buddy","family":"Creech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getahun","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Wegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2024.126702_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1179\/2047773213Y.0000000103","article-title":"Global alert to avian influenza virus infection: from H5N1 to H7N9","volume":"107","author":"Poovorawan","year":"2013","journal-title":"Pathog Glob Health"},{"issue":"13","key":"10.1016\/j.vaccine.2024.126702_bb0010","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza a (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2024.126702_bb0015","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza a\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126702_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofz107","article-title":"Safety and immunogenicity of mf59-adjuvanted cell culture\u2013derived a\/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly","volume":"6","author":"Frey","year":"2019","journal-title":"Open Forum of Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126702_bb0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiv087","article-title":"Safety and immunogenicity of a single low or high dose of clade 2 H5N1 inactivated influenza vaccine in adults previously primed with clade 1 H5N1","volume":"212","author":"Winokur","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126702_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu091","article-title":"Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant","volume":"1","author":"Chen","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126702_bb0035","article-title":"Point-of-use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety. A phase 1 clinical trial. Open forum","volume":"1","author":"Mulligan","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.126702_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/CVI.00475-15","article-title":"Persistence of antibody to influenza a\/H5N1 vaccine virus: impact of AS03 adjuvant","volume":"23","author":"Chen","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126702_bb0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.vaccine.2018.11.069","article-title":"Safety and immunogenicity of influenza a(H5N1) vaccine stored up to twelve years in the national pre-pandemic influenza vaccine stockpile (NPIVS)","volume":"37","author":"Oshansky","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126702_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac983","article-title":"Safety and immunogenicity of a monovalent inactivated influenza a\/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults","author":"Winokur","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126702_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac982","article-title":"Safety and immunogenicity of influenza a\/H5N8 virus vaccine in healthy adults: durability and cross-reactivity of antibody responses","author":"Neuzil","year":"2023","journal-title":"CID"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126702_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-021-00287-7","article-title":"Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza a(H7N9) elicits high and sustained antibody responses in healthy adults","volume":"6","author":"Oshansky","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126702_bb0065","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/infdis\/jiz295","article-title":"Stockpiled avian influenza a(h7n9) vaccines induce robust, nonneutralizing functional antibodies against antigenically drifted fifth-wave a(H7N9) viruses","volume":"220","author":"Zhong","year":"2019","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2024.126702_bb0070","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza a (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126702_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/infdis\/jiy408","article-title":"Antigenic drift of influenza a(H7N9) virus hemagglutinin","volume":"219","author":"Ning","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126702_bb0080","author":"Rostad","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2024.126702_bb0085","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.vaccine.2019.03.071","article-title":"Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza a\/H7N7-H7N9 vaccination","volume":"37","author":"El Sahly","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126702_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/infdis\/jiad276","article-title":"Safety and immunogenicity of a delayed heterologous influenza a(H7N9) vaccine boost following different priming regimens: a randomized clinical trial study group","volume":"229","author":"El Sahly","year":"2023","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126702_bb0095","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126702_bb0100","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.vaccine.2020.11.051","article-title":"Immunogenicity and safety of different dose schedules and antigen doses of MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older","volume":"39","author":"Winokur","year":"2021","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2024.126702_bb0105","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza a\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"issue":"234","key":"10.1016\/j.vaccine.2024.126702_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008761","article-title":"A cell culture-derived MF59-adjuvanted a\/H7N9 vaccine is immunogenic in adults","volume":"6","author":"Bart","year":"2014","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126702_bb0115","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/infdis\/jiw414","article-title":"Immunogenicity and safety of an AS03-Adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults","volume":"214","author":"Madan","year":"2016","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2024.126702_bb0120","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1016\/j.vaccine.2022.03.055","article-title":"Safety and immunogenicity of monovalent h7n9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: a randomized clinical trial","volume":"40","author":"Ortiz","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126702_bb0125","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/508174","article-title":"Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza a\/H9N2 vaccine preparations","volume":"43","author":"Atmar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126702_bb0130","series-title":"Update: Increase in human infections with novel Asian lineage avian influenza A(H7N9) viruses during the fifth epidemic - China","volume":"2017","author":"Kile","year":"2016"},{"key":"10.1016\/j.vaccine.2024.126702_bb0135","author":"Asian Lineage Low Pathogenic Avian Influenza A(H7N9) virus, Virus Strain: A\/Hong Kong\/125\/2017"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126702_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3201\/eid2401.171393","article-title":"Changing geographic patterns and risk factors for avian influenza a(H7N9) infections in humans","volume":"24","author":"Artois","year":"2018","journal-title":"China Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126702_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/v11111047","article-title":"Comparative pathogenicity and transmissibility of the H7N9 highly pathogenic avian influenza virus and the H7N9 low pathogenic avian influenza virus in chickens","volume":"11","author":"Yu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.126702_bb0150","author":"Reported human infections with avian influenza A viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126702_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3947\/ic.2013.45.2.159","article-title":"Fluad\u00ae-MF59\u00ae-Adjuvanted Influenza Vaccine in Older Adults","volume":"45","author":"Tsai","year":"2013","journal-title":"Rev Infect Chemother"},{"key":"10.1016\/j.vaccine.2024.126702_bb0160","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 \u2013 an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126702_bb0165","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2018.04.048","article-title":"VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines","volume":"36","author":"Kuck","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126702_bb0170","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1021\/ac4040778","article-title":"Quantification of viral proteins of the avian H7 subtype of influenza virus: an isotope dilution mass spectrometry method applicable for producing more rapid vaccines in the case of an influenza pandemic","volume":"86","author":"Santana","year":"2014","journal-title":"Anal Chem"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126702_bb0175","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CVI.00368-08","article-title":"Qualification of the Hemagglutination inhibition assay in support of pandemic influenza vaccine licensure","volume":"16","author":"Noah","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126702_bb0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.slasd.2023.10.008","article-title":"High-throughput cell-based immunofluorescence assays against influenza","volume":"29","author":"Martinez-Gzegozewska","year":"2024","journal-title":"SLAS Discov"},{"key":"10.1016\/j.vaccine.2024.126702_bb0185","doi-asserted-by":"crossref","unstructured":"Laura Couzens, Jin Gao, Kim Westgeest, Matthew Sandbulte, Vladimir Lugovtsev, RonFouchier, Maryna Eichelberger. \u201cAn optimized enzyme-linked lectin assay to measure influenza a virus neuraminidase inhibition antibody titers in human sera\u201d. J Virol Methods 210, pg. 7\u201314. 2014.","DOI":"10.1016\/j.jviromet.2014.09.003"},{"key":"10.1016\/j.vaccine.2024.126702_bb0190","doi-asserted-by":"crossref","unstructured":"Maryna C. Eichelberger, Laura Couzens, Yonghong Gao, Min Levine, Jacqueline Katz, Ralf Wagner, Catherine I. Thompson, Katja H\u00f6schler, Karen Laurie, Tian Bai, Othmar G. Engelhardt, John Wood, Ella study participants. \u201cComparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for theanalysis of influenza vaccine immunogenicity.\u201d Vaccine 34, pg. 458\u2013465. 2016.","DOI":"10.1016\/j.vaccine.2015.12.022"},{"key":"10.1016\/j.vaccine.2024.126702_bb0195","doi-asserted-by":"crossref","first-page":"25051","DOI":"10.1038\/srep25051","article-title":"HaynesL Age-related impairment ofhumoral response to influenza is associated with changes in antigen specific Tfollicular helper cell responses","volume":"6","author":"Lefebvre","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126702_bb0200","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.maturitas.2015.05.004","article-title":"Immunosenescence: implications for response to infection and vaccination in older people","volume":"82","author":"Pera","year":"2015","journal-title":"Maturitas"},{"issue":"25","key":"10.1016\/j.vaccine.2024.126702_bb0205","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1016\/j.vaccine.2016.04.023","article-title":"The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations","volume":"34","author":"Frasca","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126702_bb0210","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/cid\/cit255","article-title":"Stratified estimates of influenza vaccine effectiveness by prior vaccination: caution required","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126702_bb0215","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/14760584.2017.1334554","article-title":"Repeated annual influenza vaccination and vaccine effectiveness: review of evidence","volume":"16","author":"Belongia","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"24","key":"10.1016\/j.vaccine.2024.126702_bb0220","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1016\/j.vaccine.2021.04.036","article-title":"Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016","volume":"39","author":"Leung","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126702_bb0225","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/pathogens12020169","article-title":"First impressions matter: immune imprinting and antibody cross-reactivity in influenza and sars-cov-2","volume":"12","author":"King","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2024.126702_bb0230","article-title":"Cross-reactivity between avian influenza a (H7N9) virus and divergent H7 subtypic- and heterosubtypic influenza a viruses","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126702_bb0235","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1128\/JVI.03183-13","article-title":"H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge","volume":"88","author":"Florian Krammer","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126702_bb0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41541-022-00524-7","article-title":"The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination","volume":"7","author":"Goll","year":"2022","journal-title":"Npj Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126702_bb0245","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase","volume":"207","author":"Couch","year":"2013","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126702_bb0250","doi-asserted-by":"crossref","first-page":"e00416","DOI":"10.1128\/mBio.00417-16","article-title":"Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza a\/H1N1 virus healthy human challenge model","volume":"7","author":"Memoli","year":"2016","journal-title":"mBio"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T14:56:57Z","timestamp":1740236217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24013847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"alternative-id":["S0264410X24013847"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126702","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59\u00ae","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126702"}}